Metformin in neoadjuvant systemic treatment in breast cancer patients with metabolic syndrome

Любота, Р. В.; Zotov, A.S.; Верещако, Р.; Cheshuk, Valeriy; Аникусько, Н. Ф.; Любота, И И

doi:10.1093/annonc/mdw365.81

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Jiralerspong et al (2009), showed a pCR of 24% in diabetic BC patients receiving metformin compared to 8% in the control arm 5 . In addition, the trial by Liubota et al (2016), found that the rate of pCR in BC patients with metabolic syndrome receiving neoadjuvant systemic treatment was 31% in the metformin group versus 6% in the control group 45 . Furthermore, The trial by Laat et al (2016), found a statistically significant association between the pCR and metformin, pCR was achieved in 64.3% in the metformin arm versus 23.1% in the control arm 46 .…”

Section: Methodsmentioning

confidence: 99%

The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial

Barakat

Hussein

Elberry

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Recently, several clinical trials have attempted to find evidence that supports the anticancer use of metformin in breast cancer (BC) patients. The current study evaluates the anticancer activity of metformin in addition to neoadjuvant chemotherapy (NACT) in locally advanced BC patients. Additionally, we assess the safety and tolerability of this combination and its effect on the quality of life (QoL) of BC patients. Eighty non-diabetic female patients with proven locally advanced BC were randomized into two arms. The first arm received anthracycline/taxane-based NACT plus metformin. The second arm received anthracycline/taxane-based NACT only. Overall response rate (ORR), clinical complete response (cCr), pathological complete response (pCR), and breast conservative rate (BCR) were evaluated between both groups, and correlated with serum metformin concentration. ORR, cCr, pCR, and BCR increased non-significantly in the metformin group compared to the control group; 80.6% vs 68.4%, 27.8% vs 10.5%, 22.2% vs 10.5%, and 19.4% vs 13.2%, respectively. A trend towards cCR and pCR was associated with higher serum metformin concentrations. Metformin decreased the incidence of peripheral neuropathy, bone pain, and arthralgia, although worsened the gastrointestinal adverse events. Metformin combination with NACT has no effect on the QoL of BC patients. Metformin combination with NACT is safe, tolerable, and improves non-significantly the clinical and pathological tumor response of BC patients.

show abstract

Section: Methodsmentioning

confidence: 99%

The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial

Barakat

Hussein

Elberry

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A number of epidemiological, experimental and clinical studies proved that the metabolic abnormalities, associated with MS, increase the risk of breast cancer and worsen its prognosis. For example, in MS patients decreased sensitivity of the tumor to systemic anticancer therapy, increased rate of postoperative complications as well as reduced overall and disease-free survival compared to patients without MS was reported (5)(6)(7)(8). In addition, some drugs that are used in systemic anticancer therapy of breast cancer increase insulin resistance -the main pathogenetic link of MS.…”

Section: Introductionmentioning

confidence: 99%

Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome

et al. 2018

View full text Add to dashboard Cite

Background: The aim of this prospective randomized trial was to investigate the influence of metformin on the effectiveness of neoadjuvant systemic therapy in breast cancer patients with metabolic syndrome. Patients and methods: The study included 72 patients (from 31 to 77 years of age) who received neoadjuvant systemic treatment for stage II-III breast cancer at the National Medical University named after O.O Bogomolets, Municipal City Clinical Oncological Center, Department of Oncology, Kyiv during 2010-2014. Metabolic syndrome was diagnosed in all patients according to the International Diabetes Federation criteria. They were divided in two groups: group 1 that included 36 patients with metabolic syndrome and breast cancer who did not intake metformin during neoadjuvant systemic therapy, and group 2 that included 36 patients with metabolic syndrome and breast cancer who received metformin with neoadjuvant systemic therapy. Results: Complete clinical response was identified in 2 (6%) patients from group 1 and 10 (27.5%) patients from group 2. Overall clinical response rate (cCR + cPR) was achieved in 28 (77.5%) patients treated with metformin compared to 9 (25%) patients from group 1. A stable disease was observed in 19 (53%) patients who were not taking metformin. The rate of pathological complete response was 26.5% (9 patients) in the metformin group and 6% (2 patients) in the non-metformin group. Conclusions: Combined neoadjuvant systemic anticancer therapy of breast cancer patient with metabolic syndrome with metformin has a higher clinical and pathological overall response rate than treatment without metformin.

show abstract

Correction of dismetabolic manifestations in perimenopausal and early postmenopausal women with fibrocystic disease

Кишакевич¹,

Конар²

2016

Reproductive Endocrinology

View full text Add to dashboard Cite

Менопауза як біологічна подія є передвісником багатьох потенційних проблем зі здоров'ям, які можуть вплинути не лише на якість, але і часом на тривалість життя жінки [12]. Як відомо, природна менопауза передбачає закономірне припинення менструацій унаслідок зниження активності фолікулярного апарату яєчників. Про менопаузу, що настала, можна судити лише за наявності аменореї протягом 12 послідовних місяців [14]. Відлік початку менопаузи зазвичай ведеться від останньої менструації, але з упевненістю про її настання можна говорити лише через рік або більше. Іншого адекватного незалежного біологічного маркера для визначення цього явища не існує. АНАЛІЗ ЛІТЕРАТУРНИХ ДАНИХ ТА ПОСТАНОВКА ЗАВДАННЯ ДОСЛІДЖЕННЯ За даними проспективних епідеміологічних досліджень, середній вік початку переходу в стан менопаузи відповідає 45,5-47,5 рокам, і триває цей перехід в середньому 4 роки [9]. Близько 5-10% жінок перехід у стан менопаузи клінічно не відзначають, оскільки в них зберігаються регулярні менструації та відсутні симптоми дефіциту естрогену [15]. Згідно з сучасними уявленнями, в організмі жінок у перименопаузальному періоді відбуваються істотні зміни гомеостазу: знижується імунний захист, підвищується неінфекційна захворюваність і частота аутоімунних захворювань, втрачається основа кісткової тканини і розвивається остеопороз, починаються дегенеративні зміни в серцево-судинній системі. Всі клінічні прояви клімактеричного синдрому (КС) можна розділити на наступні клініко-патогенетичні групи [2, 3]: нейровегетативні-гіпо-або гіпертензія, головний біль, вестибулопатії, серцебиття у спокої, несприйняття високої температури, судоми, оніміння, «гусяча» шкіра, дермографізм, сухість шкіри, пітливість, набряки, алергічні реакції, екзофтальм, підвищена збудливість, сонливість, порушення сну, припливи жару, напади задухи, симпато-адреналові кризи;

show abstract

Metformin in neoadjuvant systemic treatment in breast cancer patients with metabolic syndrome

Cited by 3 publications

References 0 publications

The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial

The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial

Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome

Correction of dismetabolic manifestations in perimenopausal and early postmenopausal women with fibrocystic disease

Contact Info

Product

Resources

About